# US 2015/0104443 A1 · Anti-erbb2 antibody variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104443 A1
- Document ID: US20150104443A1
- Status: Published application
- Kind: A1
- Application number: 14/399,265
- Filed: 2013-04-26
- Published: 2015-04-16
- Earliest claimed: 2012-05-08
- Assignees: Chong Kun Dang Pharmaceutical Corp.
- Applicants: Chong Kun Dang Pharmaceutical Corp.
- Inventors: Seung-Kee Moon; So-Ra Park; Ki-Young An
- Web page: https://patentgrep.com/patent/US20150104443A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61P 35/00: Antineoplastic agents
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to anti-ErbB2 antibody variants or antigen-binding fragments thereof, nucleic acid molecules encoding them, and their uses. The antibody variants of the present invention are capable of binding to ErbB2 with high affinity. Therefore, the antibody variants are ability to effectively prevent or treat various cancers with a low amount.

## Claims

### Claim 1

An anti-ErbB2 antibody variant or antigen-binding fragment thereof, comprising:
(a) a light chain variable domain; and
(b) a heavy chain variable domain which amino acid sequence has at least two amino acid substitutions selected from the group consisting of: a substitution of Pro at position 41 with Arg, a substitution of Gly at position 96 with Asn, a substitution of Gly at position 97 with Ala, a substitution of Asp at position 98 with Trp, a substitution of Asp at position 98 with Lys, a substitution of Ala at position 100b with Ser, a substitution of Met at position 100c with Phe, a substitution of Asp at position 101 with Ala, a substitution of Asp at position 101 with Val, a substitution of Tyr at position 102 with His, and a substitution of Tyr at position 102 with Leu,
wherein the positions are indicative of positions on the amino acid sequence of SEQ ID NO:1, and numbered according to the Kabat numbering system.

### Claim 2 (depends on 1)

The antibody variant or antigen-binding fragment thereof according to claim 1, wherein the heavy chain variable domain comprises a substitution of Asp at position 98 with Trp, a substitution of Met at position 100c with Phe, a substitution of Asp at position 101 with Ala, and a substitution of Tyr at position 102 with Leu.

### Claim 3 (depends on 1)

The antibody variant or antigen-binding fragment thereof according to claim 1, wherein the heavy chain variable domain comprises a substitution of Gly at position 96 with Asn, a substitution of Gly at position 97 with Ala, a substitution of Asp at position 98 with Lys, a substitution of Ala at position 100b with Ser, a substitution of Met at position 100c with Phe, a substitution of Asp at position 101 with Val, and a substitution of Tyr at position 102 with His.

### Claim 4 (depends on 1)

The antibody variant or antigen-binding fragment thereof according to claim 1, wherein the heavy chain variable domain comprises a substitution of Pro at position 41 with Arg, a substitution of Asp at position 98 with Trp, a substitution of Met at position 100c with Phe, a substitution of Asp at position 101 with Ala, and a substitution of Tyr at position 102 with Leu.

### Claim 5 (depends on 1)

The antibody variant or antigen-binding fragment thereof according to claim 1, wherein the light chain variable domain is the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least two amino acid substitutions selected from the group consisting of: a substitution of Ser at position 50 of SEQ ID NO:2 with Thr, a substitution of Ala at position 51 of SEQ ID NO:2 with Thr, a substitution of Ser at position 52 of SEQ ID NO:2 with Thr, a substitution of Phe at position 53 of SEQ ID NO:2 with Trp, a substitution of Leu at position 54 of SEQ ID NO:2 with Pro, a substitution of Thr at position 72 of SEQ ID NO:2 with Ser, a substitution of His at position 91 of SEQ ID NO:2 with Tyr, a substitution of Thr at position 93 of SEQ ID NO:2 with Gln, a substitution of Thr at position 93 of SEQ ID NO:2 with Asn, a substitution of Pro at position 96 of SEQ ID NO:2 with Ala, a substitution of Pro at position 96 of SEQ ID NO:2 with Val, and a substitution of Thr at position 97 of SEQ ID NO:2 with Ser, and wherein the positions are numbered according to the Kabat numbering system.

### Claim 6 (depends on 5)

The antibody variant or antigen-binding fragment thereof according to claim 5, wherein the light chain variable domain comprises a substitution of Thr at position 93 of SEQ ID NO:2 with Gln, a substitution of Pro at position 96 of SEQ ID NO:2 with Ala, and a substitution of Thr at position 97 of SEQ ID NO:2 with Ser.

### Claim 7 (depends on 5)

The antibody variant or antigen-binding fragment thereof according to claim 5, wherein the light chain variable domain comprises a substitution of Ser at position 50 of SEQ ID NO:2 with Thr, a substitution of Ala at position 51 of SEQ ID NO:2 with Thr, a substitution of Ser at position 52 of SEQ ID NO:2 with Thr, a substitution of Phe at position 53 of SEQ ID NO:2 with Trp, a substitution of Leu at position 54 of SEQ ID NO:2 with Pro, a substitution of Thr at position 72 of SEQ ID NO:2 with Ser, a substitution of His at position 91 of SEQ ID NO:2 with Tyr, a substitution of Thr at position 93 of SEQ ID NO:2 with Asn, and a substitution of Pro at position 96 of SEQ ID NO:2 with Val.

### Claim 8 (depends on 1)

The antibody variant or antigen-binding fragment thereof according to claim 1, which comprises the following heavy chain variable domain and light chain variable domain:
(i) a light chain variable domain of SEQ ID NO:2 and a heavy chain variable domain of SEQ ID NO:3;
(ii) a light chain variable domain of SEQ ID NO:2 and a heavy chain variable domain of SEQ ID NO:4;
(iii) a light chain variable domain of SEQ ID NO:5 and a heavy chain variable domain of SEQ ID NO:3; or
(iv) a light chain variable domain of SEQ ID NO:7 and a heavy chain variable domain of SEQ ID NO:6.

### Claim 9 (depends on 1)

The antibody variant or antigen-binding fragment thereof according to claim 1, which is a humanized antibody.

### Claim 10 (depends on 1)

A nucleic acid molecule encoding a heavy chain variable domain or a light chain variable domain of an anti-ErbB2 antibody variant or antigen-binding fragment thereof according to claim 1.

### Claim at position 11

11-13. (canceled)

### Claim 14 (depends on 1)

A method of preventing or treating a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (a) an anti-ErbB2 antibody variant or antigen-binding fragment thereof according to claim 1, and (b) a pharmaceutically acceptable carrier.
